These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28539565)

  • 1. Successful Treatment of Congestive Heart Failure Due to Severe Aortic Valve Stenosis With Low Dose Tolvaptan in Elderly Patients.
    Takasu K; Miyazaki T; Negoro K; Yatsu S; Shimizu M; Murata A; Kato T; Suda S; Hiki M; Kasai T; Miyauchi K; Daida H
    Int Heart J; 2017 May; 58(3):378-384. PubMed ID: 28539565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure.
    Kinoshita M; Okayama H; Kosaki T; Hosokawa S; Kawamura G; Shigematsu T; Takahashi T; Kawada Y; Hiasa G; Yamada T; Matsuoka H; Kazatani Y
    Heart Vessels; 2018 Feb; 33(2):163-169. PubMed ID: 28889231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan Prolongs Blockage of the Vasopressin Type II Receptor Over 24 Hours in Responders With Stage D Heart Failure.
    Imamura T; Kinugawa K; Komuro I
    Int Heart J; 2016; 57(1):41-6. PubMed ID: 26742881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure.
    Shimizu K; Doi K; Imamura T; Noiri E; Yahagi N; Nangaku M; Kinugawa K
    Nephrology (Carlton); 2015 Jun; 20(6):405-12. PubMed ID: 25619790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical safety and efficacy of tolvaptan for acute phase therapy in patients with low-flow and normal-flow severe aortic stenosis.
    Mitsui M; Kataoka A; Nara Y; Nagura F; Kawashima H; Hioki H; Nakashima M; Watanabe Y; Yokoyama N; Kozuma K
    Heart Vessels; 2019 Oct; 34(10):1684-1691. PubMed ID: 30993439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry.
    Murakami T; Watanabe Y; Nakamura N; Natsumeda M; Ohno Y; Nakazawa G; Ikari Y; Kataoka A; Nishihata Y; Hayashida K; Yamamoto M; Tanaka J; Jujo K; Izumo M; Mizutani K; Kozuma K
    Heart Vessels; 2024 Aug; 39(8):687-695. PubMed ID: 38710808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Tolvaptan in Patients with Aortic Stenosis.
    Shimozono K; Fukumoto Y
    Kurume Med J; 2022 Mar; 67(1):11-16. PubMed ID: 34840201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with long-term administration of tolvaptan to patients with acute decompensated heart failure.
    Kiuchi S; Fujii T; Hisatake S; Kabuki T; Takashi O; Dobashi S; Ikeda T
    Drug Discov Ther; 2017 Jul; 11(3):133-139. PubMed ID: 28626112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
    Imamura T; Kinugawa K; Shiga T; Kato N; Muraoka H; Minatsuki S; Inaba T; Maki H; Hatano M; Yao A; Kyo S; Nagai R
    Circ J; 2013; 77(2):397-404. PubMed ID: 23131721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
    Costello-Boerrigter LC; Boerrigter G; Cataliotti A; Harty GJ; Burnett JC
    Circ Heart Fail; 2010 May; 3(3):412-9. PubMed ID: 20176717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Heart Vessels; 2018 Apr; 33(4):367-373. PubMed ID: 29128961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Shiga T; Hatano M; Yao A; Kyo S; Komuro I
    Circ J; 2013; 77(5):1208-13. PubMed ID: 23318562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolvaptan can improve clinical course in responders.
    Imamura T; Kinugawa K; Minatsuki S; Muraoka H; Kato N; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Int Heart J; 2013; 54(6):377-81. PubMed ID: 24309447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.